Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides

Biochemistry
C MouldsR W Wagner

Abstract

Antisense gene inhibition occurs when an oligonucleotide (ON) has sufficient binding affinity such that it hybridizes its reverse complementary target RNA and prevents translation either by causing inactivation of the RNA (possibly by RNase H) or by interfering with a cellular process such as stalling a ribosome. The mechanisms underlying these processes were explored. Cellular antisense inhibition was evaluated in a microinjection assay using ON modifications which precluded or allowed in vitro RNase H cleavage of ON/RNA hybrids. RNase H-independent inhibition of protein synthesis could be achieved by targeting either the 5'-untranslated region or the 5'-splice junction of SV40 large T antigen using 2'-O-allyl phosphodiester ONs which contained C-5 propynylpyrimidines (C-5 propyne). Inhibition at both sites was 20-fold less active than inhibition using RNase H-competent C-5 propyne 2'-deoxy phosphorothioate ONs. In vitro analysis of association and dissociation of the two classes of ONs with complementary RNA showed that the C-5 propyne 2'-O-allyl phosphodiester ON bound to RNA as well as the C-5 propyne 2'-deoxy phosphorothioate ON. In vitro translation assays suggested that the two classes of ONs should yield equivalent anti...Continue Reading

References

Nov 27, 1992·Science·J C HanveyK G Au
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Gossen, H Bujard
Aug 15, 1990·Biochemical Pharmacology·B J Dolnick
Feb 1, 1988·Molecular and Cellular Biology·R W Wagner, K Nishikura
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R W WagnerK Nishikura
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P DashP Goelet
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R Y Walder, J A Walder
Nov 11, 1994·Nucleic Acids Research·H E JohanssonM W Hentze
Sep 4, 1993·Lancet·M A KirklandJ M Goldman
Jul 9, 1993·Journal of Medicinal Chemistry·J F MilliganJ C Martin

❮ Previous
Next ❯

Citations

Oct 8, 1998·Advances in Enzyme Regulation·M Egli
May 10, 2003·Brain Research. Brain Research Reviews·Dirk Van OekelenJosée E Leysen
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton
Mar 19, 2002·Advanced Drug Delivery Reviews·Yoshinori Kakizawa, Kazunori Kataoka
Jun 7, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·I LebedevaM Vilenchik
Jul 1, 1996·Nature Biotechnology·R W WagnerB C Froehler
Sep 1, 1996·Nature Biotechnology·W M FlanaganR W Wagner
May 4, 2001·Antisense & Nucleic Acid Drug Development·L MeunierA C Roche
Apr 1, 1997·Antisense & Nucleic Acid Drug Development·J SummertonM Partridge
Dec 2, 2008·Nucleic Acids Research·Montserrat Terrazas, Eric T Kool
Oct 6, 1998·Annual Review of Biochemistry·S Verma, F Eckstein
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·C Frank Bennett, Eric E Swayze
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·W M FlanaganM D Matteucci
Sep 21, 2001·Nucleosides, Nucleotides & Nucleic Acids·A ArzumanovM J Gait
Oct 4, 2005·Journal of Drug Targeting·Barbara RuoziMaria Angela Vandelli
Oct 30, 2015·Future Medicinal Chemistry·Vivek K Sharma, Jonathan K Watts
Jul 18, 2001·The Journal of Urology·I LebedevaC A Stein
Jun 11, 2002·Biochemical and Biophysical Research Communications·Makoto MatsukuraKazuo Shinozuka
Jul 17, 2004·Annual Review of Biomedical Engineering·Charles M Roth, Sumati Sundaram
Mar 19, 1999·Methods : a Companion to Methods in Enzymology·D L Sokol, A M Gewirtz
Aug 24, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·R B Flatschart, M C Sogayar
Jan 27, 1999·Nature Biotechnology·W M FlanaganM D Matteucci
Dec 10, 2003·Oncogene·Nicholas M Dean, C Frank Bennett
Jul 14, 2020·Medicinal Research Reviews·Epaminondas Doxakis
Jan 1, 1995·Antisense Research and Development·R W Wagner
Jun 6, 2003·Journal of the American Chemical Society·Brent M ZnoskoDouglas H Turner
Mar 31, 2005·Journal of the American Chemical Society·Agnes NoyModesto Orozco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.